Full-Time

Head of Formulation and Drug Product Development

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Discovers and develops therapeutic antibodies

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

CA$152.9k - CA$229.3kAnnually

+ Equity + Annual Bonus

Senior, Expert

Vancouver, BC, Canada

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • 12-15+ years of industry experience with a PhD in a relevant scientific discipline. Strong candidates with BSc or MSc degrees may be considered with sufficient Process Development and leadership experience
  • 6+ years of experience building, leading, and developing a cross-functional team
  • Experience in establishing and running a Formulation Development team for monoclonal antibodies and other protein biologics
  • Experience establishing phase-appropriate first-in-human formulation development strategies, including stability evaluation, biophysical characterization, and clinical in-use evaluation
  • Experience overseeing the execution of formulation and drug product development activities at CDMO partner sites
  • Experience in working closely with Quality teams to establish workflows that enable successful documentation, data capture, and data integrity, ensuring compliance with industry standards
  • Deep knowledge of global regulatory expectations for the development of protein biologics, including experience supporting INDs, CTAs, and other regulatory filings. Direct experience interacting with regulatory agencies and health authorities is desired
  • Bias towards innovation over industry standards, keen to do things differently, and passionate about building dynamic teams and capabilities that accomplish important goals
  • Strongly self-motivated and able to identify project needs and follow that up with building and implementing solutions
  • Experience with device development and/or antibody-drug conjugates
Responsibilities
  • Further developing the overall strategy for all aspects of formulation, drug product, and clinical in-use development for therapeutic antibodies
  • Developing the formulation and drug product team and workflows to deliver appropriate formulations and drug products for AbCellera’s pipeline
  • Supporting and providing strategic guidance to meet near and long term clinical demands with a network of CMOs and CDMOs, as needed
  • Providing a beginning-to-end solution for all aspects of antibody formulation development
  • Working closely with AbCellerites to develop an innovative approach to CMC development that is closely integrated with our antibody discovery and development workflows
  • Developing workflows for screening and selecting lead antibody molecules with optimal developability and manufacturing properties
  • Preparing regulatory documents and communicating with health authorities
  • Continuously driving improvements to the established processes, increasing speed and efficiency while meeting regulatory requirements

AbCellera focuses on discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera excels at addressing challenging targets that traditional methods struggle with. The company's goal is to advance new treatments to market while generating revenue through partnerships, discovery services, and its own therapeutic programs.

Company Stage

IPO

Total Funding

$620.9M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

3%

1 year growth

5%

2 year growth

25%
Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Biogen could lead to breakthroughs in neurological treatments.
  • Partnership with Eli Lilly expands AbCellera's reach in diverse therapeutic areas.
  • Acquisition of Dualogics' platform strengthens AbCellera's competitive position.

What critics are saying

  • Peter Thiel's resignation may impact strategic guidance and investor confidence.
  • High-risk research with Biogen could lead to delays or failures.
  • Resource allocation challenges may arise from multiple new biotech ventures.

What makes AbCellera Biologics unique

  • AbCellera's platform integrates diverse scientific approaches for efficient antibody discovery.
  • The company excels in tackling challenging targets with innovative methods.
  • AbCellera's strategic partnerships enhance its antibody development capabilities.

Help us improve and share your feedback! Did you find this helpful?